Literature DB >> 30847724

Smad Anchor for Receptor Activation and Phospho-Smad3 Were Upregulated in Patients with Temporal Lobe Epilepsy.

Wenbo Zhang1,2, Yingshi Du2, Yan Zou2, Jing Luo3, Yang Lü2, Weihua Yu4.   

Abstract

Smad anchor for receptor activation (SARA) is an important regulator of transforming growth factor β (TGF-β) signaling by recruiting Smad2/3 to TGF-β receptors. We recently demonstrated that the expressions of SARA and level of downstream phospho-Smad3 (p-Smad3) were upregulated in the brain in the epileptic rat model, but were never examined in patients with temporal lobe epilepsy (TLE). In this study, we examined the expressions of SARA and level of p-Smad3 in brain tissues of TLE patients using immunohistochemistry and western blot to demonstrate that SARA activation in neurons is sufficient to facilitate TGF- β pathway in patients to regulate epilepsy. We found that the expressions of SARA and level of p-Smad3 were significantly upregulated in neurons of the temporal cortex of TLE patients compared to controls. Moreover, SARA and p-Smad3 were strongly stained in the cytoplasm in the temporal cortex of TLE patients. Our results indicate that upregulation of SARA and p-Smad3 in cortex neurons might be involved in the development of intractable temporal lobe epilepsy.

Entities:  

Keywords:  Patient; SARA; Seizure; Smad3; TGF-β; Temporal lobe epilepsy

Mesh:

Substances:

Year:  2019        PMID: 30847724     DOI: 10.1007/s12031-019-01285-0

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  2 in total

Review 1.  TGF-β as a Key Modulator of Astrocyte Reactivity: Disease Relevance and Therapeutic Implications.

Authors:  Jian Luo
Journal:  Biomedicines       Date:  2022-05-23

2.  A somatic mutation in MEN1 gene detected in periventricular nodular heterotopia tissue obtained from depth electrodes.

Authors:  Laura Montier; Zulfi Haneef; Jay Gavvala; Daniel Yoshor; Robert North; Terence Verla; Paul C Van Ness; Janice Drabek; Alica M Goldman
Journal:  Epilepsia       Date:  2019-09-06       Impact factor: 5.864

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.